SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Tatva Chintan Pharma Chem informs about transcript of earnings call

19 May 2026 Evaluate

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, Tatva Chintan Pharma Chem has informed that it enclosed the transcript of the earnings call held on 16 May 2026 post announcement of financial results of the Company for the quarter and financial year ended 31 March 2026. The above information shall be made available on Company’s website of at www.tatvachintan.com.

The above information is a part of company’s filings submitted to BSE.


Tatva Chintan Pharma Share Price

1195.00 -2.15 (-0.18%)
19-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
SRF 2709.30
BASF India 3492.00
Tata Chemicals 729.50
Pidilite Inds. 1579.50
Deepak Nitrite 1645.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: